Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04944134 · ClinicalTrials.gov registry record
COVID-19 Antibody Levels After Vaccines
A clinical trial, sponsored by University of North Carolina, Chapel Hill.
- Completed
- Registry status
- 71
- Enrollment target
NCT04944134 is a clinical trial that has completed, run by University of North Carolina, Chapel Hill. The registered enrollment target is 71 participants.
The verdict
NCT04944134 has completed, sponsored by University of North Carolina, Chapel Hill.
- COMPLETED
- Registry status
- 71 participants
- Enrollment target
Study Summary
This study will measure the levels of nasal mucosal Immunoglobulin A (IgA) and blood serum IgA up to one year after COVID vaccination, as well as examining what factors might affect antibody levels in the nose. This will be done through nasal epithelial lining fluid collection and standard venipuncture.
Interventions
- BIOLOGICAL COVID-19 Vaccination
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 71 participants |
| Start Date | 2021-06-09 |
| Est. Completion | 2022-04-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04944134
The ClinicalTrials.gov registry entry for NCT04944134 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 71 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of North Carolina, Chapel Hill, which has 1,109 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which COVID-19 Vaccination is the first listed.
NCT04944134 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04944134 about?
NCT04944134 is a clinical study titled "COVID-19 Antibody Levels After Vaccines". This study will measure the levels of nasal mucosal Immunoglobulin A (IgA) and blood serum IgA up to one year after COVID vaccination, as well as examining what factors might affect antibody levels in the nose. This will be done through nasal epithelial lining fluid collection and standard venipunct...
What is the current status of trial NCT04944134?
This trial is currently completed. The enrollment target is 71 participants. The study started on 2021-06-09. Estimated completion is 2022-04-01.
What interventions are being tested in trial NCT04944134?
The interventions under investigation include: COVID-19 Vaccination (BIOLOGICAL).
Who is sponsoring clinical trial NCT04944134?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.